Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The recent fall can be attributed to the Q2FY23 results the company reported yesterday, with revenue falling below and earnings above our estimates.

Should You Buy Medtronic Stock At $80?

Albemarle

Clorox

Ecolab

Essex Property Trust

W.W. Grainger

Lowe's

ProShares S&P 500 Dividend Aristocrats ETF

Nucor

Realty Income Corp

Roper Technologies

Sherwin-Williams

Stanley Black & Decker

Sysco

Target

V.F.

West Pharmaceutical Services

NOBL gained 10.31% in October, which brings the Fund's return for the year to a loss of 8.96%. Thus far this month, through November 22nd, the dividend aristocrat ETF is up 6.52%, bringing its year-to-date return to -3.03%.

My Best Dividend Aristocrats For December 2022

DUBLIN , Nov. 23, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the Evercore ISI 5th annual HealthCONx conference on Tuesday, November 29, 2022.  Geoff Martha, Medtronic chairman and chief executive officer, and Karen Parkhill, executive vice president & chief financial officer, will answer questions on the company beginning at 5:10 p.m.

Medtronic executives to speak at the Evercore ISI 5th annual HealthCONx conference

Supply-chain and demand challenges pressure the Dublin-based company's latest quarterly results.

Medtronic Stock Falls After Medical-Device Maker Posts Lower Earnings

Analog Devices

These 2 Stocks Just Made Surprising Moves

Medtronic's (MDT) Q2 organic revenues reflect slower supply recovery and lower-than-anticipated underlying market procedure volumes in certain businesses.

Medtronic (MDT) Q2 Earnings Beat Estimates, Margins Down

Medtronic plc (NYSE:MDT ) Q2 2023 Earnings Conference Call November 22, 2022 8:00 AM ET Company Participants Ryan Weispfenning - Vice President and Head, Investor Relations Geoff Martha - Chairman and Chief Executive Officer Karen Parkhill - Chief Financial Officer Brad Welnick - Investor Relations Que Dallara - Executive Vice President and President, Diabetes Operating Unit Sean Salmon - Executive Vice President and President, Cardiovascular Portfolio Brett Wall - Executive Vice President and President, Neuroscience Portfolio Bob White - Executive Vice President and President, Medical Surgical Portfolio Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America Vijay Kumar - Evercore ISI Larry Biegelsen - Wells Fargo Matt O'Brien - Piper Sandler Josh Jennings - Cowen & Company Matt O'Brien - Piper Sandler Matt Taylor - Jefferies Pito Chickering - Deutsche Bank Joanne Wuensch - Citi Ryan Weispfenning Good morning. I am Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations and welcome to snowing Minneapolis.

Medtronic plc (MDT) Q2 2023 Earnings Call Transcript

Medtronic (MDT) delivered earnings and revenue surprises of 1.56% and 1.72%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Q2 Earnings Surpass Estimates

Medtronic reported mixed earnings and lighter-than-expected organic sales growth, leading MDT stock to tumble. The post Medical Behemoth Medtronic Crumbles After Missing Its Own Guidance appeared first on Investor's Business Daily.

Medical Behemoth Medtronic Crumbles After Missing Its Own Guidance

The medical device maker misses fiscal second-quarter sales expectations and lowers its earnings guidance for the year.

Medtronic Lowers Earnings Guidance, Citing Slower Procedure and Supply Recovery

Shares of Medtronic PLC MDT, +1.22% dropped 2.4% in premarket trading Tuesday, after the medical devices maker reported fiscal second-quarter profit that topped expectations but revenue that missed and provided a downbeat full-year outlook, citing weakness in procedure volumes in certain businesses and the pricing impact of procurement in China. Net income for the quarter to Oct. 28 fell to $427 million, or 32 cents a share, from $1.31 billion, or 97 cents a share, in the year-ago period.

Medtronic stock falls after profit beats expectations but revenue misses, and outlook is downbeat

Earnings delivered despite slower market procedure volume and supply recovery; Growth driven by TAVR, Pacing, U.S. Core Spine, and International Diabetes DUBLIN , Nov. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2023, which ended October 28, 2022. Key Highlights Revenue of $7.6 billion decreased 3% as reported and increased 2% organic GAAP diluted EPS of $0.32 decreased 67%; non-GAAP diluted EPS of $1.30 decreased 2% Company updates guidance; expects organic revenue to accelerate in second half "We're taking decisive actions to improve the performance of the company.

Medtronic reports second quarter fiscal 2023 financial results

Microsoft

Procter & Gamble

Verizon

The end of the year is usually an excellent time to look for deals. In 2022, a bear market caused by rising interest rates in response to the highest inflation in four decades punished stock prices.

4 No-Brainer Dividend Stocks for the End of 2022

AbbVie

Ally Financial

These stocks offer attractive yields now, and investors can look forward to lots of payout raises.

3 Top Dividend Stocks to Buy Now With Yields of 3.4% or More

MongoDB

Block

These impressive businesses seem to have plenty of room for further growth.

3 Unstoppable Growth Stocks to Buy and Hold for the Next Decade

American Eagle Outfitters

iQIYI

The three major U.S. equity indexes closed lower Thursday. The Dow Jones industrials ended the day down 0.02%, the S&P 500 closed 0.31% lower and the Nasdaq retreated 0.35%.

Earnings Previews: American Eagle Outfitters, iQIYI, Medtronic

Medtronic (NYSE: MDT) is scheduled to report its fiscal 2023 second-quarter results on Tuesday, November 22. We expect Medtronic﻿﻿ to post revenues and earnings in line with the street estimates.

Will Medtronic Stock See Higher Levels Post Q2 Results?

Baxter

Centene

CVS Health

Edwards Lifesciences

Zoetis

Zoetis and Medtronic are among the healthcare stocks with the most room to rise, according to Wall Street analysts' average price targets.

6 Healthcare Stocks With Room to Climb

Abbott Labs

Merck

Premier

UnitedHealth Group

Here are six health-care stocks with low-risk fundamentals, reasonable debt, good price-earnings ratios, sanguine growth projections and healthy yields.

Op-ed: Here are 6 stocks with excellent vital signs in the health-care sector

DUBLIN , Nov. 15, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2023 on Tuesday, November 22, 2022. A news release will be issued at approximately 5:45 a.m.

Medtronic to announce financial results for its second quarter of fiscal year 2023

Annual costs savings of insulin of up to 25% and plastic waste reduction of up to 50% with Medtronic Extended infusion set DUBLIN , Nov. 15, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the U.S. launch of Medtronic Extended infusion set, the first and only infusion set labelled for up to 7-day wear. An infusion set is tubing that delivers insulin from an insulin pump to the body and typically requires a set change every two to three days.

Medtronic Launches World's First and Only Infusion Set for Insulin Pumps that Doubles Wear Time up to 7 days in U.S.

Amcor Plc

Atmos Energy

Franklin Resources

Federal Realty Investment Trust

Coca-Cola

Leggett & Platt

T. Rowe Price Group

Walgreens

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing. 65 Aristocrats screened as of November 8, 2022 represented all eleven Morningstar sectors. Broker-estimated top-ten net gains ranged 11.21%-36.63%, topped by MDT & ESS.

Walgreens Named November Aristocrats Top Dog

Medtronic is a premium quality enterprise that trades at a significant discount to its historical valuations. It has a long runway of growth with exposure to popular health categories.

Medtronic: Buy This 'A' Quality Gem On The Cheap

The company has applied for FDA approval of Symplicity Spyral, an experimental device used to perform a minimally invasive treatment procedure.

Medtronic Blood-Pressure Device Curbs Hypertension, but Misses Top Goal in Study

DUBLIN and CHICAGO , Nov. 7, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clinical trial. The data were presented today as Late-Breaking Clinical Science at the American Heart Association (AHA) Scientific Sessions 2022.

SPYRAL HTN-ON MED study demonstrates meaningful clinical benefits consistent with other SPYRAL HTN renal denervation trials

News for Medtronic Stock (MDT)